Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells

DNA Repair

Volumn 7, Issue 2, 2008, Pages 239-252

  Hill, Richard ^a   Leidal, Andrew M ^a   Madureira, Patricia A ^b   Gillis, Laura D ^a   Cochrane, Haley K ^a   Waisman, David M ^b   Chiu, Arthur ^c   Lee, Patrick W K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Apoptosis; Chromium; DNA damage; p21; p53

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHROMIUM; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA; SYNAPTOPHYSIN;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL DEATH; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; EXPOSURE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERSENSITIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WILD TYPE;

ANNEXIN A5; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CHROMIUM; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION; HUMANS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37549006412     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dnarep.2007.10.001     Document Type: Article

References (32)

1. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
2. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
3. Waldman T., Kinzler K.W., and Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55 (1995) 5187-5190
4. Chipuk J.E., and Green D.R. Cytoplasmic p53: bax and forward. Cell Cycle 3 (2004) 429-431
5. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
6. Schuler M., Maurer U., Goldstein J.C., Breitenbucher F., Hoffarth S., Waterhouse N.J., and Green D.R. p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death. Differ. 10 (2003) 451-460
7. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., and Vogelstein B. A model for p53-induced apoptosis. Nature 389 (1997) 300-305
8. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., and Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
9. Gartel A.L., Serfas M.S., and Tyner A.L. p21-negative regulator of the cell cycle. Proc. Soc. Exp. Biol. Med. 213 (1996) 138-149
10. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
11. Chan T.A., Hwang P.M., Hermeking H., Kinzler K.W., and Vogelstein B. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev. 14 (2000) 1584-1588
12. Fei P., Bernhard E.J., and el-Deiry W.S. Tissue-specific induction of p53 targets in vivo. Cancer Res. 62 (2002) 7316-7327
13. Fotedar R., Bendjennat M., and Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle 3 (2004) 134-137
14. Suzuki A., Tsutomi Y., Akahane K., Araki T., and Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17 (1998) 931-939
15. Suzuki A., Tsutomi Y., Miura M., and Akahane K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 18 (1999) 1239-1244
16. Xu S.Q., and el-Deiry W.S. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem. Biophys. Res. Commun. 269 (2000) 179-190
17. Li Y., Dowbenko D., and Lasky L.A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 277 (2002) 11352-11361
18. O'Brien T.J., Ceryak S., and Patierno S.R. Complexities of chromium carcinogenesis: role of cellular response, repair and recovery mechanisms. Mutat. Res. 533 (2003) 3-36
19. Salnikow K., Zhitkovich A., and Costa M. Analysis of the binding sites of chromium to DNA and protein in vitro and in intact cells. Carcinogenesis 13 (1992) 2341-2346
20. Bose R.N., Fonkeng B.S., Moghaddas S., and Stroup D. Mechanisms of DNA damage by chromium(V) carcinogens. Nucleic Acids Res. 26 (1998) 1588-1596
21. Strauss J.K., and Maher III L.J. DNA bending by asymmetric phosphate neutralization. Science 266 (1994) 1829-1834
22. O'Brien T.J., Fornsaglio J.L., Ceryak S., and Patierno S.R. Effects of hexavalent chromium on the survival and cell cycle distribution of DNA repair-deficient S. cerevisiae. DNA Repair (Amst.) 1 (2002) 617-627
23. Bridgewater L.C., Manning F.C., Woo E.S., and Patierno S.R. DNA polymerase arrest by adducted trivalent chromium. Mol. Carcinog. 9 (1994) 122-133
24. Manning F.C., Xu J., and Patierno S.R. Transcriptional inhibition by carcinogenic chromate: relationship to DNA damage. Mol. Carcinog. 6 (1992) 270-279
25. Ha L., Ceryak S., and Patierno S.R. Chromium (VI) activates ataxia telangiectasia mutated (ATM) protein. Requirement of ATM for both apoptosis and recovery from terminal growth arrest. J. Biol. Chem. 278 (2003) 17885-17894
26. Wakeman T.P., and Xu B. ATR regulates hexavalent chromium-induced S-phase checkpoint through phosphorylation of SMC1. Mutat. Res. 610 (2006) 14-20
27. Grayson S., and Elias P.M. Human epidermal proteolipids: isolation, partial characterization, and subcellular localization. J. Invest Dermatol. 90 (1988) 185-192
28. Kaeser M.D., and Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 95-100
29. Mattia M., Gottifredi V., McKinney K., and Prives C. p53-dependent p21 mRNA elongation is impaired when DNA replication is stalled. Mol. Cell Biol. (2006) 1309-1320
30. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 (2001) 402-408
31. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
32. Broude E.V., Demidenko Z.N., Vivo C., Swift M.E., Davis B.M., Blagosklonny M.V., and Roninson I.B. p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle 6 (2007) 1468-1471